Hedgehog Pathway Inhibitors and Their Utility in Basal Cell Carcinoma: A Comprehensive Review of Current Evidence
Abstract Basal cell carcinoma (BCC) is the most commonly diagnosed malignancy in humans, and as such it poses a significant healthcare burden. The majority of BCC cases are amenable to cure by surgical extirpation. However, until recently there have been no good treatment options for a significant m...
Main Authors: | Evelyn Yu-Xin Tay, Yee-Leng Teoh, Matthew Sze-Wei Yeo |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2018-12-01
|
Series: | Dermatology and Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1007/s13555-018-0277-7 |
Similar Items
-
Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib
by: Jaeyoung Yoon, MD, PhD, et al.
Published: (2018-01-01) -
A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature
by: Anna Passarelli, et al.
Published: (2020-11-01) -
Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis
by: Yuchen Li, et al.
Published: (2019-07-01) -
Treatment of periocular advanced basal cell carcinoma with Hedgehog pathway inhibitors: a single-center study and a new dedicated therapeutic protocol
by: Vincenzo De Giorgi, et al.
Published: (2021-08-01) -
Use of the Hedgehog signaling pathway inhibitor in the treatment of recurrent locally advanced and metastatic basal cell skin cancer
by: Z. A.-G. Radzhabova, et al.
Published: (2020-02-01)